Screening for Monoclonal Gammopathy in Individuals Undergoing Physical Examinations Using iMS-LC Assay Technology.

Launched by JIAN LI · Jun 28, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new test called the iMS-LC Assay, which helps detect a specific type of protein called M-proteins in the blood. M-proteins can be associated with conditions like Monoclonal Gammopathy of Undetermined Significance (MGUS), which can sometimes lead to more serious health issues. The researchers want to see how well this new test works compared to standard tests and to find out how common MGUS is among people who are having regular check-ups.

To participate in the trial, individuals must be at least 30 years old and have had certain blood tests done as part of their routine physical exams. This study is not yet recruiting participants, but once it starts, those who are eligible can expect to provide blood samples for testing. The goal is to improve the way we screen for M-proteins and better understand their presence in the general population.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• 1. Clinical patients:
• • ≥18 years old;
• • have concurrent SPEP + SIFE + FLC test results.
• 2. Individuals undergoing routine physical examinations:
• • ≥30 years old;
• • have concurrent SPEP test results.
• Exclusion Criteria:
• • NA